Buprenorphine/granisetron controlled release - Camurus/Braeburn

Drug Profile

Buprenorphine/granisetron controlled release - Camurus/Braeburn

Alternative Names: BB0417; CAM 2058

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Camurus
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Cyclopropanes; Indazoles; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Postoperative nausea and vomiting; Postoperative pain

Most Recent Events

  • 28 Nov 2016 Camurus files an clinical trial application in Sweden for Postoperative pain and Postoperative nausea and vomiting
  • 24 Oct 2016 Buprenorphine/granisetron licensed to Braeburn Pharmaceuticals in North America
  • 24 Oct 2016 Preclinical trials in Postoperative pain and Postoperative nausea and vomiting (Prevention) in Sweden (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top